It is essential to show the importance of early detection of markers of BBB dysfunction, such as exosomes carrying Aβ and tau proteins, for the introduction of therapeutic strategies aimed to limit or stop progression to cognitive impairment. This evidence concerns the gene MAPT and Cognitive impairment.